Program
taragarestrant
Also written as “D-0502” and “[14C]-D-0502”.
Its studies are mostly in Breast Neoplasms, led by InventisBio.
Furthest: phase 3, since Dec 20, 20245 company-led studies, 1 open or runningNext primary completion: Nov 30, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InventisBio | 51 open or running | phase 3since Dec 20, 2024 | Mar 14, 2018 | Nov 30, 2026phase 3 · NCT06954961 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 14, 2018First study: phase 1 study in Breast NeoplasmsFirst studyNCT03471663 · 200 enrolled · United States, China
- Dec 16, 2018Phase 1 study in Breast NeoplasmsNCT03810625 · 14 enrolled · United States
- Oct 22, 2021Phase 1 study in Healthy Female VolunteerNCT05226338 · 18 enrolled · United States
- Mar 25, 2022Phase 1 study in Mass Balance RecoveryNCT05339633 · 8 enrolled · United States
- Dec 20, 2024Phase 3 study in Breast NeoplasmsNCT06954961 · 640 planned · China
Ahead
- Nov 30, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT06954961
TargetBeta
ESR1 →read by rule
“An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), ”NCIt, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06954961Breast Neoplasms · China | 3 | Recruiting | Nov 30, 2026 | 640 |
| NCT05339633Mass Balance Recovery · United States | 1 | Completed | Aug 2, 2022 | 8 |
| NCT05226338Healthy Female Volunteer · United States | 1 | Completed | Dec 23, 2021 | 18 |
| NCT03810625Breast Neoplasms · United States | 1 | Completed | Nov 21, 2018 | 14 |
| NCT03471663Breast Neoplasms · United States, China | 1 | Completed | Oct 18, 2023 | 200 |
How it is read
Names in the registry
- “D-0502”, 4 entries
- “[14C]-D-0502”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.